翻訳と辞書 |
NSI-189
NSI-189 is an experimental drug being studied by Neuralstem, Inc. Research into NSI-189 has been funded by the Defense Advanced Research Projects Agency (DARPA) and the National Institutes of Health (NIH) for the treatment of major depressive disorder.〔 ==Clinical trials== NSI-189 successfully completed a phase 1 clinical trial in 2011 where it was administered to 41 healthy volunteers.〔(Single-Dose Pharmacokinetics (PK) Study of Novel Neurogenic Compound NSI-189 )〕 A phase 1b clinical trial for treating major depressive disorder in 24 patients started in 2012 and completed in July 2014.〔(Multiple-Dose Pharmacokinetics (PK), and Pharmacodynamic (PD) Effect of NSI-189 Phosphate in Depression Patient Subjects )〕〔()〕 The study suggests that there were improvements in the patients' condition when the doses were 40/80 mg per day, but no significant improvements were seen for a higher dosage of 120 mg/day. Neuralstem intends to pursue further clinical trials for a variety of neurological conditions, including major depressive disorder, traumatic brain injury, Alzheimer's disease, post-traumatic stress disorder,〔(FDA Approves Neuralstem To Treat Final Cohort In NSI-189 Phase Ib Trial In Major Depressive Disorder )〕 stroke, and natural cognitive and memory decline in aging.
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「NSI-189」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|